secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122322
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss
------------------------------------------------------------------------------

- NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).
- Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.
- Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.
- Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.
- Health Canada approved DAYBUE for Rett syndrome under Priority Review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/0000950170-24-122322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/acad-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer